APEIRON Biologics AG and Domainex Ltd announce the expansion of their partnership to progress targeted cancer immune therapy drug discovery

Integrated lead optimisation to advance APEIRON’s Cbl-b inhibitor development programme APN431 Inhibitors discovered at Domainex via virtual and fragment screening Press release (EN) | Presseaussendung (DE)
November 9, 2020
View the Post